Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label ascending-dose study of ACE-536 in adults with beta-thalassemia intermedia
2012-002499-15Phase 2Completed
- Sponsor
- Acceleron Pharma Inc.
- Start
- Sep 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of luspatercept in beta-thalassemia intermedia, sponsored by Acceleron Pharma Inc. Primary endpoint: Erythroid response. Started Sep 2012; status: completed.
02
Drugs
luspatercept
03
Conditions
beta-thalassemia intermedia
Beyond the preview
Go deeper on 2012-002499-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002499-15.